CT:PRN Profound Medical Corp.

Profound Medical Corp. operates as a medical technology company develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol PROF.

This company has cross-listed shares that trade in the U.S. as the symbol PROF.

12.64 CAD
As of 03/24/2023

---

Security Information

---

Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Unknown
Industry:  Medical Devices
Index country:  Canada
Country of incorporation:  Canada
IPO date:  01/01/1900
Stock exchange:    Toronto Stock Exchange
Exchange country:   Canada
Market cap:   187,015,504 CAD
Current dividend yield:   0.00%
Sedol: